Despite implementation of new interventional techniques and therapeutic advances, elderly patients with acute coronary syndrome (ACS) continue to be susceptible to in-hospital bleeding compared with younger ones. Thus, we investigated the incidence of in-hospital bleeding events and associated risk factors in elderly (≥ 75°years) ACS patients. We also wanted to define the bleeding sites, characteristics, and associated mortality. Bleeding Academic Research Consortium (BARC) classification type 2, 3, or 5 was used to define bleeding events. Overall, 539 patients were included in the study (mean age: 82.5 ± 4.8°years; 282 (52.3%) females). Of these patients, 69 (12.8%) developed in-hospital bleeding. Factors that were independently related with in-hospital bleeding were age (odds ratio (OR): 1.08; 95% confidence interval (CI): 1.011.14, P = .01), acute kidney injury (OR: 3.66; 95% CI: 2.016.69; P < .01), tirofiban (OR: 4.43; 95% CI: 1.7810.99; P < .01), and ticagrelor (OR: 1.93; 95% CI: 1.013.73; P = .04) administration. The urinary tract was the most frequent bleeding site, followed by femoral arteries. In conclusion, ticagrelor and tirofiban should be used with caution in elderly ACS patients.
TownsendNWilsonLBhatnagarPWickramasingheKRaynerMNicholsM. Cardiovascular disease in Europe: Epidemiological update 2016. Eur Heart J. 2016;37:3232–3245.
2.
MoranAEForouzanfarMHRothGAMensahGAEzzatiMMurrayCJNaghaviM, et al.Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to 2010: The global burden of disease 2010 study. Circulation. 2014;129:1483–1492.
3.
BenjaminEJBlahaMJChiuveSECushmanMDasSRDeoR, et al.Heart disease and stroke statistics’2017 update: A report from the American heart association. Circulation. 2017;135:e146–e603.
4.
RichMWChyunDASkolnickAHAlexanderKPFormanDEKitzmanDW, et al.Knowledge gaps in cardiovascular care of the older adult population. Circulation. 2016;133:2103–2122.
5.
FoxKACarruthersKStegPGAvezumAGrangerCBMontalescotG, et al.Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? the global registry of acute coronary events. Eur Heart J. 2010;31:667–675.
6.
MehranRPocockSNikolskyEDangasGDClaytonTClaessenBE, et al.Impact of bleeding on mortality after percutaneous coronary intervention: Results from a patient-level pooled analysis of the REPLACE-2 (Randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (Acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (Harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials. JACC Cardiovasc Interv. 2011;4:654–664.
7.
IbanezBJamesSAgewallSAntunesMJBucciarelli-DucciCBuenoH, et al.2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018;39:119–177.
8.
LeveyASBoschJPLewisJBGreeneTRogersNRothD, et al.A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med. 1999;130:461–470.
9.
MehtaRLKellumJAShahSVMolitorisBARoncoCWarnockDG, et al.Acute kidney injury network: Report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11:R31.
10.
MehranRRaoSvBhattDLGibsonCMCaixetaAEikelboomJ, et al.Standardized bleeding definitions for cardiovascular clinical trials: A consensus report from the bleeding academic research consortium. Circulation. 2011;123:2736–2747.
11.
SubherwalSBachRGChenAYGageBFRaoSVNewbyLK, et al.Baseline risk of major bleeding in non-sT-segment- elevation myocardial infarction the CRUSADE (can rapid risk stratification of unstable angina patients suppress ADverse outcomes with early implementation of the ACC/AHA guidelines) bleeding score. Circulation. 2009;119:1873–1882.
12.
MehranRPocockSJNikolskyEClaytonTDangasGDKirtaneAJ, et al.A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol. 2010;55:2556–2566.
13.
MathewsRPetersonEDChenAYWangTYChinCTFonarowGC, et al.In-hospital major bleeding during st-elevation and nonst-elevation myocardial infarction care: Derivation and validation of a model from the action registry®-GWTGTM. Am J Cardiol. 2011;107:1136–1143.
14.
Ariza-SoléAFormigaFLorenteVSánchez-SaladoJCSánchez-ElviraGRouraG, et al.Efficacy of bleeding risk scores in elderly patients with acute coronary syndromes. Rev Española Cardiol. 2014;67:463–470.
15.
FaustinoAMotaPSilvaJ. Síndromes coronárias agudas sem supradesnivelamento-ST nos octogenários: aplicabilidade dos scores GRACE e CRUSADE. Rev Port Cardiol. 2014;33:617–627.
16.
WallentinLBeckerRCBudajACannonCPEmanuelssonHHeldC, et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–1057.
17.
GimbelMQaderdanKWillemsenLHermanidesRBergmeijerTde VreyE, et al.Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): The randomised, open-label, non-inferiority trial. Lancet. 2020;395:1374–1381.
18.
ChangCJTungYCLiuJRChangSHKuoCTSeeLC. Efficacy and safety of ticagrelor vs. clopidogrel in east asian patients with acute myocardial infarction: A nationwide cohort study. Clin Pharmacol Therapeut. 2021;109:443–451.
19.
NeumannFJSousa-UvaMAhlssonAAlfonsoFBanningAPBenedettoU, et al.2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2019;40:87–165.
20.
D’AscenzoFGrossoAAbu-AssiEKinnairdTAriza-SoléAManzano-FernándezS, et al.Incidence and predictors of bleeding in ACS patients treated with PCI and prasugrel or ticagrelor: An analysis from the RENAMI registry. Int J Cardiol. 2018;273:29–33.
21.
GarayAAriza-SoléAFormigaFRaposeiras-RoubínSAbu-AssiESánchez-SaladoJC, et al.Prediction of post-discharge bleeding in elderly patients with acute coronary syndromes: Insights from the BleeMACS registry. Thromb Haemostasis. 2018;118:929–938.
22.
ZhouXWuXSunHLiJ. Efficacy and safety of eptifibatide versus tirofiban in acute coronary syndrome patients: A systematic review and meta-analysis. J Evid Base Med. 2017;10:136–144.
23.
GermingABojaraWLawoTEwersAGrewePMüggeA, et al.Bleeding complications associated with glycoprotein IIb/IIIa inhibitors in patients 80 years of age and older undergoing percutaneous coronary intervention. Exp Clin Cardiol. 2010;15:e57–60.
24.
LopesRDWhiteJATricociPWhiteHDArmstrongPWBraunwaldE, et al.Age, treatment, and outcomes in high-risk non‐ST-segment elevation acute coronary syndrome patients: Insights from the EARLY ACS trial. Int J Cardiol. 2013;167:2580–2587.
25.
Ariza-SoléAGuerreroCFormigaFAboalJAbu-AssiEMarínF, et al.Global geriatric assessment and in-hospital bleeding risk in elderly patients with acute coronary syndromes: Insights from the LONGEVO-SCA registry. Thromb Haemostasis. 2018;118:581–590.
26.
ColletJPThieleHBarbatoEBarthélémyOBauersachsJBhattDL, et al.2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2020;42:1289–1367.
27.
LiYHFangCYHsiehICHuangWCLinTHSungSH, et al.2018 expert consensus on the management of adverse effects of antiplatelet therapy for acute coronary syndrome in Taiwan. Acta Cardiol Sin. 2018;34:201–210.
28.
KunoTNumasawaYMikamiTNiimiNSawanoMKodairaM, et al.Association of decreasing hemoglobin levels with the incidence of acute kidney injury after percutaneous coronary intervention: A prospective multi-center study. Heart Ves. 2021;36:330–336.
29.
OhnoYMaekawaYMiyataHInoueSIshikawaSSueyoshiK, et al.Impact of periprocedural bleeding on incidence of contrast-induced acute kidney injury in patients treated with percutaneous coronary intervention. J Am Coll Cardiol. 2013;62:1260–1266.
30.
TonelliMLloydAMBelloAKJamesMTKlarenbachSWMcAlisterFA, et al.Statin use and the risk of acute kidney injury in older adults. BMC Nephrology. 2019;20:103.
31.
ZhouXDaiJXuXWangZXuHChenJ, et al.Comparative efficacy of statins for prevention of contrast-induced acute kidney injury in patients with chronic kidney disease: A network meta-analysis. Angiology. 2019;70:305–316.
